Pipedream - Good question. The problem is we have no idea what percentage of that $24 million would belong to SCRC, nor do we know the margins. So in an effort to be consistent with our UPOD model, I simply took 20% of $24 million to account for everything from percentage to SCRC, to sales commissions, to COGS, to adminstrative expenses, charge backs and refunds, and taxes to arrive at earnings of $4,800,000 attributable to Guts's $2 million per month example of his friend's compounding pharmacy business. (Though this would be a 300% increase over SCRC's reported specialty revenue March 2014 sales, I do believe it is reasonable to assume this amount or even more in the next 12 to 24 months.) I also conisdered 135 million shares outstanding and a PE of 20, which may appear a bit high, but I actually expect a much higher PE as this great company accelerates earnings quarter after quarter.

I hope this helps